The combined approach group had better bone progression-free survival ( BPFS ) ( 9.0 vs. 6.0 months , P < 0.05 ) and overall survival ( OS ) ( 19.0 vs. 15.0 months , P = 0.02 ) , but no statistical evidence of benefit was observed in terms of PSA response .